Messina M S
St. Luke's Hospital, New Bedford, Massachusetts, USA.
Adv Ther. 1995 May-Jun;12(3):157-63.
Patients with reversible bronchospasm benefit from the use of inhaled beta-adrenergic agents. In this retrospective study of 24 older patients with a variety of conditions associated with reversible bronchospasm--asthma, asthma with emphysema, chronic bronchitis, and asthmatic bronchitis--symptomatic improvement was noted after treatment with inhaled bitolterol mesylate. Symptoms resolved or improved after 1 month in 93.8% (15/16) of patients using a metered-dose inhaler and in 75% (6/8) of those using a hand-held nebulizer. Sixteen additional patients were randomly selected to undergo pulmonary function tests after receiving two to three puffs of bitolterol from a metered-dose inhaler. FEV1 improved by 10.9%, FVC by 12.1%, and FEF25%-75% by 34.4% after administration of bitolterol. No adverse events were noted in any patients in either group. The results of this retrospective study suggest that bitolterol is an effective and safe treatment in patients with conditions associated with reversible bronchospasm.
可逆性支气管痉挛患者可从吸入β-肾上腺素能药物的使用中获益。在这项对24例患有与可逆性支气管痉挛相关的多种病症（哮喘、合并肺气肿的哮喘、慢性支气管炎和喘息性支气管炎）的老年患者的回顾性研究中，吸入甲磺酸比托特罗治疗后症状有改善。使用定量吸入器的患者中93.8%（15/16）在1个月后症状缓解或改善，使用手持式雾化器的患者中75%（6/8）有此效果。另外16例患者在从定量吸入器吸入两到三喷比托特罗后被随机选择进行肺功能测试。给予比托特罗后，第1秒用力呼气容积（FEV1）提高了10.9%，用力肺活量（FVC）提高了12.1%，25%～75%用力呼气流量（FEF25%-75%）提高了34.4%。两组中任何患者均未观察到不良事件。这项回顾性研究的结果表明，比托特罗对患有与可逆性支气管痉挛相关病症的患者是一种有效且安全的治疗方法。
